America asks for the best price

You drive a new pickup home proud of the deal, then learn your brother-in-law paid $3,000 less for the same truck from the same lot. Same truck, same dealer. He just knew to ask.

For decades that was America at the pharmacy counter. In the May 2025 executive order that started this push, the White House noted that Americans are less than 5% of the world's population but fund about three quarters of global drug-company profits, paying almost three times more for the same medicines.

Most Favored Nation pricing is the brother-in-law's move written into a contract. Whatever your best price is for a comparable wealthy country, America gets that price too.

Twenty-six signatures

Since that order, 26 drugmakers have signed MFN agreements, covering 89% of the branded drug market by the White House's count. The latest nine, announced August 31, include Teva, Sun Pharma, CSL and UCB. Those August deals give every state Medicaid program access to MFN prices and guarantee MFN prices on new medicines the companies bring to market. The 26 companies have also committed about $170 billion to American manufacturing and research.

There was leverage behind the handshakes. A 100% tariff on patented drugs took effect July 31 for large manufacturers, and companies with MFN deals are exempt through January 2029.

What changes in Medicaid

Under a CMS program called GENEROUS, participating drugmakers pay rebates to state Medicaid programs so the final price does not exceed the MFN price. On September 18 the White House announced that all 50 states, D.C. and Puerto Rico had signed on. The Council of Economic Advisers puts the savings at $64.3 billion over ten years: $36.6 billion for Washington and $27.6 billion for the states.

The contracts are not public, and a Medicaid patient already pays a copay of roughly $4 to $8, so she will not notice a thing. Critics are right on both counts, and the secrecy is why the council's biggest number, $600 billion in total savings over a decade, is an estimate, not a receipt. But the patient was never the one overpaying. The taxpayer was, and these savings land in federal and state budgets that every working family funds.

The sticker price on American medicine was never a law of nature. It was a negotiation, and this time America walked onto the lot and asked for the best price.